Specific Aim of this Innovative Molecular Analysis Technologies (IMAT) SBIR Phase I grant proposal is to show the feasibility of a high-throughput molecular technology for discovery of monoclonal antibody (mAb) drugs for oncology from human B cell repertoires. Drug companies spend up to $5 billion to produce a single FDA-approved monoclonal antibody, or mAb (DiMasi &Grabowski, 2007;Nelson et al., 2010). High mAb development cost is at least partly due to the high failure rate of candidates. A technology that improves mAb selection by just 10% before entering clinical development could save the drug industry ~$400 million per FDA- approved mAb. Immune systems are "test tubes" that constantly select for antibodies with strong potential as drugs. GigaLink" will be a research service for drug discovery programs that leverages these antibody selection test tubes. In mouse systems, our technology could eventually replace B cell immortalization. In human systems, our technology could eventually replace phage display. Antibody fragments identified in our DNA libraries will be easily modified into mAbs, because they are fully human, are already known to express on the surface of B cells, and have already shown positive selection in vivo. In Phase I we will integrate our current molecular and bioinformatic methods with mammalian expression and affinity screening. The project will focus on antibody fragments against epidermal growth factor receptor (EGFR), because many anti-EGFR biologics are available to help us test our system. Though we focus on EGFR, the primary outcome of this project is platform development - ideal for the IMAT program at the National Cancer Institute (NCI). We will accomplish the Specific Aim by performing the following tasks: (i) Optimize mammalian expression and affinity screening using known anti-EGFR antibody fragments;(ii) Implement computational methods for quantitatively integrating genomic and affinity data;and (iii) Screen pancreatic cancer patient B cells for anti-EGFR antibody fragments. To be successful, we must achieve the following metrics: (i) Recover >80% of known anti-EGFR antibody fragments by mammalian expression and affinity screening (power=0.8, ?=0.05);and (ii) Use germline divergence rates and affinity screening to discover no less than ten anti-EGFR antibody fragments with affinity constant (Kaff)<10-7 and significant sequence evolution rates (power=0.8,?=0.05). In Phase II, we will focus on laboratory and computational methods for affinity maturation of fully human monoclonal antibodies from GigaLink" antibody fragments. Once Phase II is complete, GigaGen will compete directly with mAb discovery services such as Morphosys and Adimab. Future grant applications will focus on oncology targets for discovery and development of GigaGen-proprietary drugs for pancreatic cancer targets (Dodson et al., 2011), but this will only be possible once the current IMAT project has been completed.

Public Health Relevance

Better methods for discovery of antibodies could eventually lead to drugs for treatment of a variety of diseases and conditions, including cancer. We are building a novel technology that uses microfluidics, DNA sequencing, and mammalian cell display to capture and characterize new therapeutic antibodies from immune cells in human blood.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-OTC-K (10))
Program Officer
Rahbar, Amir M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Gigagen, Inc.
San Francisco
United States
Zip Code